type 2 diabetes mellitus
Conditions
Interventions
After use of SGLT2-inhibitor (dapagliflozin 5mg daily) , the oral glucose tolerance test and glucose clamp test are used, and we assess glucose, insulin, glucagon and c-peptide over time.
SGLT2 inhibitor
Sponsors
Sakaguchi Kazuhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetes mellitus 2) doctor think patients need dapagliflozin 3) non-user of other SGLT2i in one month 4) 20 to 75 years old 5) patients can understand order of take medicine 6) patients can take informed consent 7) fasting glucose controlled under 130 mg/dL
Exclusion criteria
Exclusion criteria: 1) Plegnancy 2) a rash which one had in past illness by hypoglycemic agent or insulin 3) type 1 diabetes mellitus include SPIDDM and other diabetes 4) liver dysfunction of high grade 5) renal dysfunction of high grade 6) cardiac dysfunction of high grade 7) user of basal insulin or long-acting GLP-1 receptor agonists 8) a mentally challenged person 9) patient who made recently hypoglycemia 10) patient who dapagliflozin is administrated contraindication 11) patietnt who doctor think inadequate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parameter calculated from mathematical model | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose, insulin, c-peptide, glucagon | — |
Contacts
Public ContactKazuhiko Sakaguchi
Kobe University Hospital
Outcome results
None listed